Masimo (MASI)
(Delayed Data from NSDQ)
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Zacks News
Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 1.39% and 1.74%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Abiomed Gets CDSCO Nod for Impella Heart Pumps in India
by Zacks Equity Research
Abiomed's (ABMD) Impella gets regulatory approval in India; prospects in APAC look upbeat.
Baxter (BAX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Baxter (BAX) gains on the back of its core Renal Care segment in Q2; solid international sales encourage.
Stryker (SYK) Beats on Q2 Earnings, International Sales Up
by Zacks Equity Research
Stryker (SYK) gains from solid segmental performance in Q2.
Medidata (MDSO) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Medidata (MDSO) gains from solid segmental performance in Q2; banks on strategic buyouts.
Merit Medical (MMSI) Beats on Q2 Earnings, Raises Guidance
by Zacks Equity Research
Merit Medical (MMSI) gains from solid segmental performance in Q2; lifts 2018 guidance.
OPKO Health's RAYALDEE Gets Approval in Canada to Treat CKD
by Zacks Equity Research
OPKO Health's (OPK) partner VFMCRP gets regulatory nod from Health Canada to market flagship RAYALDEE; benefits patients diagnosed with chronic kidney disease.
Intuitive Surgical's FDA Approval for SureForm to Aid Surgery
by Zacks Equity Research
Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.
MASI or STE: Which Is a Better Investment Option Right Now?
by Zacks Equity Research
Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo's (MASI) raised guidance for 2018 and strong fundamentals make it a lucrative pick.
Integer Holdings Offloads AS&O, Focuses on Cardiac Units
by Zacks Equity Research
Integer Holdings (ITGR) divests core AS&O unit to MedPlast, LLC for $600 million; aims to focus on cardiac business.
MOHAP Selects Masimo's (MASI) Eve for CCHD Screening in UAE
by Zacks Equity Research
Masimo's (MASI) Eve with Rad-97 Pulse CO-Oximeter to be integrated in nine hospitals across UAE for CCHD screening in newborns.
Masimo's (MASI) US Launch of TIR-1 to Aid Patient Monitoring
by Zacks Equity Research
Masimo (MASI) along with Thermomedics launches TIR-1 in the United States, market prospects look solid.
Why Is Masimo (MASI) Up 9.2% Since Its Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance
by Zacks Equity Research
Masimo's (MASI) impressive growth in overseas markets drives the bottom line in Q1. New products, including NomoLine capnography and O3 organ oximetry, are major catalysts.
Medical Product Stock Earnings on May 2: CERN, ABC & More
by Zacks Equity Research
Given the solid prospects in the U.S. medical products industry, here we take a peek at four major Medical Product companies scheduled to report results on May 2.
Masimo Gets CE Mark for NomoLine, Expands in Capnography
by Zacks Equity Research
Masimo (MASI) upgrades respiratory monitoring through the newly-approved Rad-97 Pulse Co-Oximeter with integrated capnography sampling lines.
Why Masimo (MASI) Could Beat Earnings Estimates Again
by Zacks Equity Research
Masimo (MASI) can be a harbinger of outperformance and a signal for a strong earnings profile on the back of solid Zacks rank and positive earnings ESP.
Masimo (MASI) Launches UniView, Improves Patient Safety
by Zacks Equity Research
Masimo's (MASI) strategy to target hospitals and consumer market is likely to provide it a competitive edge in the U.S. MedTech sector.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) rides on solid earnings results and a wide array of products.
Masimo (MASI) Beats on Q4 Earnings & Revenues, View Positive
by Zacks Equity Research
Strong performance in Product revenues drove Masimo's (MASI) fourth-quarter 2017 results.
Masimo Products to Boost India-Based NU Hospitals' Systems
by Zacks Equity Research
Masimo's (MASI) flagship technologies to be incorporated in India-based NU Hospitals' continuum of care.
Masimo's SpHb Hemoglobin Monitoring Study Results Positive
by Zacks Equity Research
New study proves that Masimo's (MASI) noninvasive SpHb is more efficient in hemoglobin monitoring when compared to invasive LabHb.
Masimo's (MASI) Eve Gets CE Mark, Bolsters CCHD Diagnosis
by Zacks Equity Research
Masimo's (MASI) newborn screening application, Eve, will make CCHD diagnosis simple and cost effective.
Masimo (MASI) Receives FDA Approval for SedLine, Shares Up
by Zacks Equity Research
Masimo (MASI) to overhaul neurological diagnoses with its next generation SedLine brain function monitoring.